Previously, we designed and synthesized DHW-221, as a dual PI3K/mTOR inhibitor, and we showed that it exerts a potent antitumor activity against NSCLC cells in vitro and in vivo (23, 24). This evidence concerns the gene MTOR and non-small cell lung carcinoma.